Ratings Anshan Hifichem Co., Ltd.

Equities

300758

CNE100003JV6

End-of-day quote Shenzhen S.E. 23:00:00 28/04/2024 BST 5-day change 1st Jan Change
9.89 CNY -0.90% Intraday chart for Anshan Hifichem Co., Ltd. +7.27% -2.18%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
  • The company's profit outlook over the next few years is a strong asset.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.45 times its estimated earnings per share for the ongoing year.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
-2.18% 553M -
+5.18% 1.75B
B+
+5.41% 979M
D+
+9.13% 966M -
+64.31% 752M - -
-2.47% 692M - -
+29.53% 600M
B-
+15.68% 499M -
-0.59% 424M -
D+
-22.73% 405M -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300758 Stock
  4. Ratings Anshan Hifichem Co., Ltd.